NEW YORK--(BUSINESS WIRE)--Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product ...
The company anticipates top-line data from the Voyage study in the first half of 2026, followed by Panorama and Emerge in the second half of 2026. MM120 ODT trials aim to address the unmet needs of ...
Chief Financial Officer Brandi Roberts said the company is preparing for several key clinical and regulatory milestones for DT-120, including anticipated Phase III data in major depressive disorder la ...
Mind Medicine (MindMed) MNMD is developing its lead pipeline candidate, MM120, an orally disintegrating tablet (ODT) and a pharmaceutically optimized form of lysergide D-tartrate (LSD), for the ...
Hosted on MSN
MindMed outlines 2026 Phase III trial readouts and advances MM120 commercialization with new CFO
Earnings Call Insights: Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 CEO Robert Barrow highlighted that MindMed remains "on track with enrollment with our three pivotal Phase III trials for our lead ...
-- Anticipated topline data readouts on track for ongoing Phase 3 studies of MM120 Orally Disintegrating Tablet (ODT) in GAD: Voyage (1H 2026) and Panorama (2H 2026)-- --Anticipated topline data ...
- Emerge is the first Phase 3 study of lysergide D-tartrate (LSD) in MDD; primary endpoint will measure change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) score at Week 6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results